Over the last decade, an increasing proportion of circulating human influenza A(H3N2) viruses exhibited haemagglutination activity that was sensitive to neuraminidase inhibitors. This change in haemagglutination as compared to older circulating A(H3N2) viruses prompted an investigation of the underlying molecular basis. Recent human influenza A(H3N2) viruses were found to agglutinate turkey erythrocytes in a manner that could be blocked with either oseltamivir or neuraminidase-specific antisera, indicating that agglutination was driven by neuraminidase, with a low or negligible contribution of haemagglutinin. Using representative virus recombinants it was shown that the haemagglutinin of a recent A(H3N2) virus indeed had decreased activity to agglutinate turkey erythrocytes, while its neuraminidase displayed increased haemagglutinating activity. Viruses with chimeric and mutant neuraminidases were used to identify the amino acid substitution histidine to arginine at position 150 flanking the neuraminidase catalytic site as the determinant of this neuraminidase-mediated haemagglutination. An analysis of publicly available neuraminidase gene sequences showed that viruses with histidine at position 150 were rapidly replaced by viruses with arginine at this position between 2005 and 2008, in agreement with the phenotypic data. As a consequence of neuraminidase-mediated haemagglutination of recent A(H3N2) viruses and poor haemagglutination via haemagglutinin, haemagglutination inhibition assays with A(H3N2) antisera are no longer useful to characterize the antigenic properties of the haemagglutinin of these viruses for vaccine strain selection purposes. Continuous monitoring of the evolution of these viruses and potential consequences for vaccine strain selection remains important.
INTRODUCTION
Influenza A viruses are responsible for the majority of seasonal influenza virus infections in humans [1] , with A(H3N2) and A(H1N1pdm09) being the current predominant virus subtypes. During influenza epidemics, severe illness occurs in up to five million people worldwide each year, with an estimated 500 000 deaths [2] [3] [4] . The almost continuous accumulation of amino acid changes in the surface glycoprotein haemagglutinin (HA) and neuraminidase (NA) of seasonal influenza viruses facilitates viral escape from antibody-mediated immunity of the human host induced by prior infections or vaccinations. This antigenic evolution facilitates multiple reinfections of the same individual during a lifetime and makes a biannual review process necessary to keep the seasonal influenza vaccine components up to date [5] .
Influenza virus particles contain two major transmembrane glycoproteins on the surface: HA and NA. Both HA and NA interact with host cells during infection, but with opposing activities. The globular head of the HA molecule contains a receptor-binding site that interacts with N-acetylneuraminic acid (sialic acid, SA), the virus receptor on host cells, to initiate infection [6, 7] . Binding of HA to SAs on erythrocytes can result in haemagglutination, i.e. clumping of red blood cells, the process from which HA obtained its name. In contrast, the viral NA protein has enzymatic activity to cleave SAs from host cells and from otherwise self-aggregating viral progeny, ensuring efficient release of virus particles during the budding process [7, 8] . A functional balance between the activities of HA and NA is important because of their opposing roles during influenza virus replication. Viruses with reduced or no NA activity can accumulate compensatory substitutions in the HA gene upon serial passage that result in a lower affinity of HA to cellular receptors [7] [8] [9] [10] . The HA-NA balance does not necessarily only relate to the efficiency of binding and cleavage, it can also relate to substrate specificity [11] . HA and NA derived from avian influenza viruses bind SAs attached via a-2,3 linkage to the terminal galactose of glycans (a-2,3SA), while the HA of human viruses has a preference for a-2,6-linked sialic acids (a-2,6SA) [12] . The NA activity of human influenza viruses retains a preference for a-2,3SA, potentially to allow cleavage of a-2,3SA present in the mucus of the human respiratory tract [13] .
Changes in HA affinity to erythrocytes from different species have been observed occasionally since influenza A(H3N2) viruses have been circulating in the human population [14] [15] [16] [17] . Since the early 2000s, several groups have observed changes in the haemagglutination behaviour of influenza A(H3N2) viruses, i.e. reduced haemagglutination of commonly used erythrocytes (turkey, chicken and guinea pig erythrocytes) and poor inhibition of haemagglutination by reference post-infection ferret antisera [11, [18] [19] [20] [21] [22] . In addition to the changes in the haemagglutination behaviour of HA, the NA activity of influenza A(H3N2) viruses isolated between 2005 and 2009 was also affected [18] . The amino acid substitution aspartic acid to glycine at position 151 (151DG) in NA was shown to cause binding of NA to erythrocytes, which could be reversed by addition of the NAinhibitor oseltamivir in the haemagglutination assay [18] . However, the vast majority of recent A(H3N2) viruses with similar changes in haemagglutination behaviour did not have 151DG in NA. Here, we describe another amino acid substitution, histidine to arginine at position 150 (150HR), flanking the catalytic site of NA, that confers haemagglutination activity upon recent A(H3N2) viruses via NA.
RESULTS
Changes in the haemagglutination activity of A(H3N2) virus isolates from 2000 to 2016 Driven by our own observations and previous reports [18] [19] [20] , the haemagglutination activity of 83 influenza A (H3N2) viruses isolated in MDCK cells from 2000 until 2016 was investigated (Table S1 , available in the online Supplementary Material), from which a representative subset is shown in Table 1 
Effect of neuraminidase in haemagglutinationinhibition assays
The oseltamivir-mediated inhibition of the haemagglutination of influenza viruses indicated a potential role for NA in the haemagglutination process. If true, this would pose problems for haemagglutination inhibition (HI) assays and complicate the antigenic characterization of the HA of circulating viruses for the purpose of influenza vaccine strain selection. A pair of virus isolates was used to investigate the role of NA in HI assays, one with normal haemagglutination activity (A/NL/109/03) and one that lost haemagglutination activity in the presence of oseltamivir (A/NL/ 761/09). We used post-infection ferret antisera raised against A(H3N2) virus isolates from the years 2003 and ability to agglutinate turkey erythrocytes efficiently and NA gained the ability to bind to turkey erythrocytes. To assess the specificity of said NA binding to red blood cells, we used turkey erythrocytes that were reconstituted to contain either a-2,3SA or a-2,6SA alone, and found that haemagglutination by viruses with the 2009 NA occurred primarily via a-2,6SA (Table S2) .
NA binding to turkey erythrocytes is due to amino acid substitution 150HR next to the NA catalytic site Two chimeric NAs were designed to identify which molecular changes in NA were responsible for the ability to agglutinate turkey erythrocytes, thereby splitting the seven amino acid differences observed between the 2003 and 2009 NA (150HR, 194VI, 215IV, 310HY, 370SL, 372LS and 387KN) over two chimeras ( (Table 3) . Unfortunately, we were not able to rescue a recombinant virus with one of the chimeric NAs (NA-1) and the HA of the 2009 virus isolate. However, the other chimeric NA (NA-2), along with the 2009 HA, yielded a viable recombinant virus with haemagglutination activity that was sensitive to the addition of oseltamivir, suggesting that the NA-dependent agglutination of turkey erythrocytes was determined by one to three amino acid substitutions in the N-terminal half of NA (150HR, 194VI and 215IV). These three amino acid substitutions were then introduced (Table 3) . Thus, we conclude that the 150HR substitution was the major determinant of NAmediated haemagglutination of the 2009 A(H3N2) virus. The 2003 NA with the 150HR substitution was binding via a-2,6SA and also via a-2,3SA (Table S2) .
Amino acid substitution 150HR in NA became dominant in recent A(H3N2) viruses The occurrence of the amino acids histidine and arginine at position 150 of NA was investigated using all of the available full-length NA gene segment sequences of human A(H3N2) full-virus genomes from 2000 to 2016 (Fig. 3) . (Tables 1 and S1 ). Of the 5942 NA sequences investigated, 1687 sequences were generated by the direct sequencing of clinical samples and 900 sequences were generated upon virus isolation in MDCK cells, but this history had no effect on the proportion of histidine and arginine at position 150 in the dataset (data not shown), indicating that substitution 150HR was not the result of passaging viruses in cell cultures. 
DISCUSSION
Here it is shown that an increasing proportion of recent influenza A(H3N2) viruses agglutinated commonly used erythrocytes in a manner that can be blocked by the NAinhibitor oseltamivir or NA-specific antibodies. This unusual haemagglutination behaviour was the result of two phenomena: a decrease in haemagglutination activity by HA and the acquisition of haemagglutination activity by NA. Amino acid substitution 150HR in NA was found to be responsible for the agglutination of turkey and human type O erythrocytes and this substitution has recently become dominant in A(H3N2) viruses. Fluctuations of the haemagglutination activity of HA have been observed in the past, due to amino acid changes in the HA of influenza A(H3N2) and A(H1N1) viruses that led to the inability to agglutinate chicken erythrocytes [14] [15] [16] . Because erythrocytes of different animal species contain different oligosaccharide structures on their surface, changes in the receptor specificity of HA of influenza viruses have been shown to correlate with differences in haemagglutination behaviour [17] . However, changes in haemagglutination behaviour do not necessarily affect the ability of influenza viruses to bind to host cells during natural infection, as the nature and density of the oligosaccharides that are present on the surface of erythrocytes do not necessarily reflect those of the glycans present on host cells and tissues. In addition, if changes in HA were to diminish the role of HA in virus attachment, influenza viruses would still have to rely on HA during virus infection because of its role in the fusion of the viral and endosomal membranes [6] .
Amino acid substitution 150HR in NA, which was identified to allow the NA-mediated agglutination of erythrocytes that can be blocked by oseltamivir and NA-specific antibodies, is adjacent to amino acid 151, a position at which another substitution (151DG) has been previously described to have a similar effect in influenza A(H3N2) viruses [18] . Amino acid positions 150 and 151 are located in the 150-loop (residues 147-152) at the edge of the catalytic site [24, 25] . However, residue 151, unlike residue 150, is categorized as a catalytic site residue and is believed to stabilize the transition state intermediate [26] . The position of these residues in or close to the catalytic site and the inhibition of NAmediated binding by oseltamivir suggest that the binding of NA to turkey erythrocytes is mediated via the catalytic site and not via haemadsorption sites, which are secondary sialic acid-binding sites that have been described for some avian NAs [27] [28] [29] [30] [31] . At the moment it is not clear what mechanism is involved in the 150HR-mediated binding of erythrocytes and what functional changes are caused in NA by this amino acid substitution. Amino acid substitution 151DG in NA has been shown to decrease NA activity, while at the same time increasing NA affinity to a-2,3SA [18, 20] . Interestingly, another amino acid substitution located in the 150-loop of NA, 147GR, has been described to mediate subtype N1 NA binding to erythrocytes [32] . Amino acid substitution 147GR did not dramatically influence NA enzymatic kinetics. However, in contrast to 151DG, the effect of 147GR on NA properties was only assessed with the surrogate substrate MUNANA. Nevertheless, it is important to note that the canonical function of NA was not affected by substitutions 151DG and 147GR, showing that these NAs still function as sialidases.
The in vivo biological significance of the amino acid substitutions in NA that have led to functional changes in the in vitro haemagglutination behaviour of influenza viruses remains unclear. However, it is important to note that influenza A(H3N2) viruses continue to cause epidemics in humans, with apparently no or little impact from these in vitro properties. While amino acid substitution 147GR in NA emerged in a recombinant laboratory strain and was only found in a small number of natural virus isolates [32] , various amino acids are found at position 151 of NA in different influenza A(H3N2) viruses [33] . However, it was found that most substitutions from 151D to different amino acids were acquired upon propagation of viruses in the laboratory [18, [33] [34] [35] [36] and that the majority of clinical samples that were not passaged in culture possessed 151D [33, 36] . Here, we investigated the occurrence of the amino acids histidine and arginine at NA position 150 in all publicly available full-genome sequences of human A(H3N2) influenza viruses since the year 2000 and found an almost complete shift from histidine to arginine over the years, regardless of whether the sequences were derived from clinical specimens or passaged viruses.
As a consequence of the loss of haemagglutination activity via HA and the increase in haemagglutination activity via NA, the antigenic characterization of HA proteins of recent influenza A(H3N2) viruses using HI assays for the biannual selection of influenza vaccine strains has become problematic [5] . In fact, for recent A(H3N2) viruses, the HI assay appears to predominantly measure the effect of antibodies against NA (Table 2) . It is therefore important to assess whether the viruses to be used in HI assays display sensitivity to oseltamivir in haemagglutination assays. If haemagglutination is found to be sensitive to inhibition by oseltamivir, virus (micro)neutralization assays could potentially be an alternative method for the antigenic characterization of influenza viruses [37, 38] . However, virus (micro) neutralization assays would only be an alternative if changes in the NA of recent H3N2 viruses did not mediate binding to cells and/or if NA neutralizing antibodies did not prevent this binding. Therefore, further investigations are needed to monitor the evolution of currently circulating H3N2 viruses and to improve our understanding of the potential consequences for the vaccine strain selection process. , were cloned in a modified pHW2000 expression plasmid [39] . Single or multiple amino acid substitutions were introduced using a QuickChange site-directed mutagenesis kit (Stratagene), according to the manufacturer's instructions. Recombinant viruses with various HA-NA combinations, as well as chimeric and mutant NA genes, were generated in the context of all other gene segments of influenza virus A/Puerto Rico/8/1934 using 293T cell transfection as previously described [40] . Virus stocks were passaged in MDCK cells up to three times. The HA and NA gene segments of all recombinant viruses were sequenced to verify the genetic modifications.
METHODS Viruses
Cells MDCK cells were grown at 37 C and 5 % CO 2 in Eagle's minimal essential medium (EMEM; Lonza) supplemented with 10 % foetal calf serum (FCS; Sigma), 100 IU ml À1 penicillin (Lonza), 100 µg ml À1 streptomycin (Lonza), 2 mM glutamine (Lonza), 10 mM HEPES buffer (Lonza), 1.5 mg ml À1 sodium bicarbonate (Lonza) and 0.1 mM non-essential amino acids (Lonza). Human embryonic kidney 293T cells were grown at 37 C and 5 % CO 2 in Dulbecco's modified Eagle medium (DMEM; Lonza) supplemented with 10 % FCS, 100 IU ml À1 penicillin, 100 mg ml À1 streptomycin, 2 mM glutamine, 1 mM sodium pyruvate (Gibco) and 0.1 mM non-essential amino acids.
Haemagglutination assay
To test haemagglutination, 50 µl virus stock was diluted using serial two fold dilutions in PBS. PBS (25 µl), with or without 20 nM oseltamivir (Roche), was added and incubated for 5 min at room temperature. Next, 25 µl of 1 % turkey or human type O erythrocytes in PBS was added and the cell and virus mixture was incubated for 1 h at 4 C before the haemagglutination titres were read.
Sequencing of HA and NA gene segments RNA of 200 µl virus-containing sample was isolated using a High Pure RNA isolation kit (Roche) according to the manufacturer's instructions. Complementary DNA (cDNA) synthesis was carried out with 22 µl viral RNA, non-coding region (NCR) primers and SuperScriptIII reverse transcriptase (Invitrogen). Subsequently, the HA or NA segment of influenza viruses was amplified with segment-specific primers. Sanger sequencing was performed on a 3130xl genetic analyser (Applied Biosystems, Hitachi).
Haemagglutination inhibition assay
Haemagglutination inhibition (HI) assays were carried out as described previously [41, 42] [23] . Pre-treatment of antisera with receptor-destroying enzyme (Vibrio cholerae NA) was carried out at 37 C overnight, followed by inactivation at 56 C for 1 h. Antisera were diluted in two fold steps with a starting dilution of 1 : 20, mixed with 25 µl virus stock of four haemagglutinating units (HAU) and incubated at 37 C for 30 min. Turkey erythrocytes (1 % in PBS, 25 l) were added and incubated for 1 h at 4 C before the haemagglutination inhibition titres were read. The reciprocal value of the highest dilution of antiserum that still completely inhibited agglutination was used to express HI titres. Haemagglutination assay with modified turkey erythrocytes Sialic acids were removed from turkey erythrocytes by incubation with Vibrio cholerae NA (VCNA; Roche) as described previously [43] . In brief, a suspension of 1 % turkey erythrocytes in PBS was incubated at 37
C for 1 h with 50 mU VCNA (1 mU µl
À1
) and 10 µl of 0.1 M CaCl 2 . Successful treatment to remove sialic acids was verified by the absence of the agglutination of erythrocytes for each virus. Resialylation of a-2,3-and a-2,6-linked sialic acids was performed using 0.5 mU of a2,3-(N)-sialyltransferase (Sigma-Aldrich) or 25 mU of a2,6-(N)-sialyltransferase (Sigma-Aldrich) and 1.5 mM CMP-sialic acid (Merck-Millipore) at 37 C in 75 µl for 2 h. After a washing step, the erythrocytes were resuspended in PBS containing 1 % bovine serum albumin to a final concentration of 0.5 %. Resialylation was confirmed by haemagglutination assays with viruses of known receptor specificity [A/Puerto Rico/8/ 1934 with HA of A/Indonesia/5/2005 (H5N1), specific for a-2,3-linked sialic acids, or A/Netherlands/213/2003 (H3N2), specific for a-2,6-linked sialic acids]. To assess the receptor specificity of the viruses of interest, standard haemagglutination assays were carried out using modified erythrocytes. Viruses that did not agglutinate normal erythrocytes with a titre of 64 were used undiluted in this assay.
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